Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer.

Recurrence was more frequent in the high ΔPNI group with marginal significance ( p = 0.06).

also in 5,069 other papers

4 a,b). On division into four subtypes (luminal; ER+ and/or PgR+ / HER2-, luminal HER2: ER+ and/or PgR+ / HER2+, HER2 enriched: ER- and PgR- / HER2+, and TNBC: ER- and PgR−/HER-), the high ΔPNI group showed a trend of poorer disease-free survival than the low ΔPNI group, although the differences were not significant because of the small number of patients with each subtype ( p = 0.091 for luminal, p = 0.098 for luminal HER2, p = 0.67 for HER2 enriched, and p = 0.18 for TNBC) (Additional file 13 : Figure S11).

also in 53,322 other papers